Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy

Core Insights - ResMed supported 26 abstracts presented at the American Thoracic Society International Conference, highlighting the effectiveness of PAP therapy in treating sleep-disordered breathing and its cardiovascular health benefits [1][10] Group 1: PAP Therapy and Sleep Disorders - Studies demonstrated that PAP therapy significantly lowers mortality rates, with a 37% reduction in patients with obstructive sleep apnea (OSA) who received treatment compared to those who did not [3] - Research indicated that PAP treatment reduces hospitalization rates in OSA patients over the first four years of treatment, correlating with decreased healthcare resource utilization [4] - The prevalence of OSA in the U.S. is projected to increase by 27.6% by 2050 among individuals aged 30-70, with an expected overall prevalence of 26% in this demographic [5][8] Group 2: GLP-1 Receptor Agonists and PAP Therapy - A study found that the use of GLP-1 receptor agonists did not increase discontinuation rates of PAP therapy; instead, patients adhering to GLP-1 medication showed higher levels of PAP therapy use [2][8] Group 3: Adaptive Servo-Ventilation (ASV) Therapy - ASV therapy was shown to reduce symptom burden and improve quality of life in patients with treatment-emergent or persistent central sleep apnea (TE-CSA) [6] - Another study indicated that ASV treatment in patients on long-term opioid therapy resulted in a median reduction in Epworth Sleepiness Scale values, reflecting lower symptom burden and improved quality of life [7] Group 4: COPD and Non-Invasive Ventilation (NIV) - Long-term home use of non-invasive ventilation (NIV) was associated with a significantly reduced risk of death in nearly 50,000 adults with chronic obstructive pulmonary disease (COPD) [9]